Preventing Relapse After Successful Electroconvulsive therapy (ECT) for Depression: A randomized controlled trial on lithium as add-on to personalized maintenance ECT

Preventing Relapse After Successful Electroconvulsive therapy (ECT) for Depression: A randomized controlled trial on lithium as add-on to personalized maintenance ECT - PRASED

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON49873

Enrollment

Registered

2020-12-23

Start date

2021-01-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression mood disorder

Interventions

In addition to ECT and antidepressants, one of the two participating groups will receive lithium. Other that that, both the procedure and the treatment and all assessments (test material) in the two

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Major depressive disorder patients - Treatment with either an adequately dosed TCA (with therapeutic blood levels) or venlafaxine (target dose of >= 225mg/day) - Remitted (IDS-C

Exclusion criteria

Exclusion criteria: - Patients with bipolar disorder, schizoaffective disorder or schizophrenia - Patients already treated with Lithium, or with a contra-indication for Lithium use - Patients with documented dementia or intellectual disability - Substance abuse or dependence in the past 6 months

Design outcomes

Primary

Measure	Time frame
Improvement of prevention of relapse by 20%	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)